Genentech, Inc.

Terence Wong

Anan Chuntharapai

Yvonne M Chen

Mark S Dennis

Lawren Wu

Mercedesz Balazs

Hans Brightbill

Wenjun Ouyang

Andrew C Chan

Patricia Valdez

Andy Chan

Dimitry Danilenko

Susan Sa

Jianfeng Wu

Yan Zheng

Jo-Anne Hongo

John B Lowe

Rajesh Vij

Keyang Xu

Yanhong Li

Luna Liu

Mauricio Maia

Cherie Louise Green

Doris Kim

Patricia Waldez

The present application relates to anti-PD-L1 antibodies and their use to detect PD-L1 in a sample from a subject. In some embodiments, the subject has been treated with a therapeutic anti-PD-L1 antibody and an anti-PD-L1 described herein does not compete for binding to PD-L1 with the therapeutic anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is linked to a N detectable moiety, such as a fluorophore and the anti-PD-L1 antibody is used to detect PD-L1 in a subject using flow cytometry.

Anti-PD-L1 antibodies and methods of using the same for detection of PD-L1

Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.

Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling

The invention provides anti-idiotypic HCMV antibodies as well as methods of using the same.

Idiotypic antibodies and uses thereof

The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.

Apoptotic anti-IgE antibodies

Nucleic acid encoding apoptotic anti-IgE antibodies

Methods of using apoptotic anti-IGE antibodies

Growing community of inventors

Alameda, CA, United States of America

Terence Wong